Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age

Vaccine. 2004 Dec 2;23(3):283-9. doi: 10.1016/j.vaccine.2004.07.017.

Abstract

Case-control study designed to determine the effectiveness of an MF59-adjuvanted influenza vaccine in the population aged 65 years and older living in the community. Detailed health histories were obtained on both cases and controls that included a functional measure of co-morbidity (Barthel Index). Subjects were all eligible persons admitted to various hospitals with a diagnosis of pneumonia during the winter months and were matched by sex, hospital and admission week to controls admitted for non-medical reasons. The influenza vaccination programme using the MF59-adjuvanted influenza vaccine significantly reduced the probability of being hospitalised for pneumonia in the elderly over 64 years of age, even in a season with a low influenza activity, during which the predominant circulating strains were types B and A (H1N1).

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study

MeSH terms

  • Adjuvants, Immunologic / administration & dosage*
  • Aged
  • Aged, 80 and over
  • Case-Control Studies
  • Emergency Service, Hospital / statistics & numerical data*
  • Female
  • Hospitalization / statistics & numerical data*
  • Humans
  • Influenza Vaccines / immunology*
  • Influenza, Human / prevention & control*
  • Male
  • Pneumococcal Vaccines
  • Pneumonia, Pneumococcal / immunology
  • Pneumonia, Pneumococcal / prevention & control*
  • Polysorbates / administration & dosage*
  • Risk Factors
  • Squalene / administration & dosage*

Substances

  • Adjuvants, Immunologic
  • Influenza Vaccines
  • MF59 oil emulsion
  • Pneumococcal Vaccines
  • Polysorbates
  • Squalene